Newron Pharmaceuticals SpA (XSWX:NWRN) Total Equity: CHF-10.39 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:NWRN Newron Pharmaceuticals SpA XSWX:NWRN
64 GF Score
Price CHF11.74
GF Value CHF13.04
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Newron Pharmaceuticals SpA Total Equity?

Newron Pharmaceuticals SpA XSWX:NWRN -0.51% 64 Total Equity is CHF-10.39 Mil as of Dec. 2025. GuruFocus rates XSWX:NWRN with a GF Score™ of 64/100 and a GF Value™ of CHF13.04 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Newron Pharmaceuticals SpA's total equity for the quarter that ended in Dec. 2025 was CHF-10.39 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Newron Pharmaceuticals SpA Total Equity Historical Data

* Premium members only.

The historical data trend for Newron Pharmaceuticals SpA's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Newron Pharmaceuticals SpA Total Equity Chart

Newron Pharmaceuticals SpA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.23 -13.85 -28.21 1.36 -10.39

Newron Pharmaceuticals SpA Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -28.21 -29.66 1.36 1.48 -10.39
XSWX:NWRN
64GF Score
Newron Pharmaceuticals SpA XSWX:NWRN
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Newron Pharmaceuticals SpA Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Newron Pharmaceuticals SpA's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=37.377-47.767
=-10.39

Newron Pharmaceuticals SpA's Total Equity for the quarter that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=37.377-47.767
=-10.39

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of CHF-10.39 Mil mean?
Newron Pharmaceuticals SpA (XSWX:NWRN) has a Total Equity of CHF-10.39 Mil as of Dec. 2025. The total amount of equity as record on a company's balance sheet. View historical data for Newron Pharmaceuticals SpA and its competitors.
Is Newron Pharmaceuticals SpA's Total Equity too high?
Newron Pharmaceuticals SpA's current Total Equity is CHF-10.39 Mil. Overall, Newron Pharmaceuticals SpA has a GF Score™ of 64/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Newron Pharmaceuticals SpA's Total Equity compare to VRTX and REGN?
Newron Pharmaceuticals SpA's Total Equity of CHF-10.39 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Newron Pharmaceuticals SpA and its competitors. Newron Pharmaceuticals SpA's current Total Equity is CHF-10.39 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Newron Pharmaceuticals SpA stock overvalued right now?
Based on GuruFocus' analysis, Newron Pharmaceuticals SpA (XSWX:NWRN) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF13.04, compared to a current price of CHF11.74 — trading 10% below its estimated fair value. The current Total Equity is CHF-10.39 Mil. Newron Pharmaceuticals SpA's overall GF Score™ is 64/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Newron Pharmaceuticals SpA (XSWX:NWRN), the current Total Equity is CHF-10.39 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Newron Pharmaceuticals SpA (XSWX:NWRN) Overvalued in 2026?

Based on GuruFocus' analysis, Newron Pharmaceuticals SpA stock appears to be undervalued. The current stock price of CHF11.74 is trading 10% below its estimated GF Value™ of CHF13.04. GuruFocus considers Newron Pharmaceuticals SpA to be Modestly Undervalued.

Key valuation signals for XSWX:NWRN:

  • Total Equity: CHF-10.39 Mil
  • GF Value™: CHF13.04 vs. price of CHF11.74 (10% below fair value)
  • GF Score™: 64/100 with 5 warning signs

No single metric tells the full story. See the XSWX:NWRN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Newron Pharmaceuticals SpA Business Description

Other Exchanges NWRNz:UK0QOI:UKNP5:Germany
Address Via Antonio Meucci 3, Bresso, Milan, ITA, 20091
Newron Pharmaceuticals SpA is a Italy-based clinical-stage biopharmaceutical company. It focuses on the discovery and development of pharmaceutical products. The Company is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The Company undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson's disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Geographically the research and development activities are performed in Italy and the United States.
64GF Score

Get the complete analysis for XSWX:NWRN

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF11.74
Price
CHF13.04
GF Value